

ABCD-ReproNim: An ABCD Course on Reproducible Data Analyses

ABCD: Introduction to Biospecimens in the ABCD Study®

Kristina Uban

Public Health

University of California, Irvine, California, USA



kuban@uci.edu



Institute for Interdisciplinary
Salivary Bioscience Research



Department of Health,
Society, and Behavior



Learning Objectives of this Lecture



- Describe the range of biospecimens in the ABCD Study®
- Describe the rationale for collecting each biospecimen in the ABCD Study®
- Summarize the methods of collection & storage for each biospecimen in the ABCD Study®
- Leverage salivary hormones to illustrate complexity of considerations for utilizing biospecimens in your statistical analyses
- Some general Do's and Don'ts when analyzing biospecimen data



Overview of biospecimens in ABCD: Baseline – Year 10?



Krista Lisdahl
Week 6

Biospecimen Samples.

Sample Type	Purpose	Baseline	1 Year Follow-Up	2 Year Follow-Up	...			
		9–10 yrs #/participant	10–11 yrs #/participant					
Screening for Alcohol & Drugs								
Saliva (onsite Dräger)*	Recent Substance Use	1	1	1				
Breath (onsite Breathalyzer)*	Recent Alcohol Use	1	1	1				
Hair (Psychemedics ^a)**	Substance Use	1	1	1				
Urine (NicAlert) ^{**}	Recent Tobacco Use	0	1	1				
Pubertal Hormones								
Saliva (Salimetrics ^b)	Pubertal Hormones	1	1	1				
Genomics/Epigenetics								
Saliva (RUCDR ^c)	Genetics	1	0					
Blood (RUCDR ^c) (saliva if refuse blood)	Genetics	0***	0	1				
Timeline of Exposures								
Baby teeth (Dr. Arora – Mt. Sinai ^d)	Environmental Exposures	1	1	1				

Methods of collection: frequency & timing



Krista Lisdahl
Week 6

Biospecimen Samples.

Sample Type	Purpose	Baseline	1 Year Follow-Up	2 Year Follow-Up	...		
		9–10 yrs #/participant	10–11 yrs #/participant	11–12 yrs			
Screening for Alcohol & Drugs							
Saliva (onsite Dräger)*	Recent Substance Use	1	1	1			
Breath (onsite Breathalyzer)*	Recent Alcohol Use	1	1	1			
Hair (Psychemedics ^a)**	Substance Use	1	1	1			
Urine (NicAlert)**	Recent Tobacco Use	0	1	1			
Pubertal Hormones							
Saliva (Salimetrics ^b)	Pubertal Hormones	1	1	1			
Genomics/Epigenetics							
Saliva (RUCDR ^c)	Genetics	1	0				
Blood (RUCDR ^c) (saliva if refuse blood)	Genetics	0***	0	1			
Timeline of Exposures							
Baby teeth (Dr. Arora – Mt. Sinai ^d)	Environmental Exposures	1	1	1			

1x/person/yr
1x/person ever*

Extra: Rationale & methods: Screening



Krista Lisdahl
Week 6

Sample Type	Purpose	Baseline	1 Year Follow-Up	2 Year Follow-Up
		9–10 yrs #/participant	10–11 yrs #/participant	
<i>Screening for Alcohol & Drugs</i>				
Saliva (onsite Dräger)*	Recent Substance Use	1	1	1
Breath (onsite Breathalyzer)*	Recent Alcohol Use	1	1	1
Hair (Psychemedics ^a)**	Substance Use	1	1	1
Urine (NicAlert) ^{**}	Recent Tobacco Use	0	1	1

- Do not want to assess participant while under influence of substances
- Collect biomarkers of history of use

The Dräger DrugTest 5000 screening test.

Drug Type	Cut-off concentration	Detection time
Amphetamine	50 ng/mL	~ 20–50 h
Benzodiazepines	15 ng/mL	~ 12–24 h
Cannabis	5 ng/mL	~ 4–16 h
Cocaine	20 ng/mL	~ 5–12 h
MDMA	75 ng/mL	~ 24 h
Methadone	20 ng/mL	~ 15 h
Methamphetamine	35 ng/mL	~ 24 h

- ‘Positive or negative’ result displayed within 5-8 min’s.
- Sensitive to lower THC levels

Extra: Rationale & methods: Screening w/ breath



- Breathalyzer for recent alcohol (BAL + time since last drink)
- Positive screens at baseline were exclusionary
- In year 1+, if positive screen, follow-up appointment scheduled to ensure no youth is tested under the influence.



Extra: Rationale & methods: Screening w/ hair




- ~10% at baseline
- ~3 month detection window
- Easy to store, still can assay hair with different shampoos or dyes
- Short hair is a limitation

parent drugs and metabolites: alcohol ethyl glucuroide (ETC), cannabis (11-Nor-9-carboxy-THC (THCCOOH) and cannabidiol (CBD)), methamphetamine and methylenedioxy-methamphetamine (MDMA), amphetamine, opiates (codeine morphine, hyrdomorph, oxycodone, hydrocodone), and cocaine/benzoylecgonine (BE).

Extra: Rationale & methods: Screening w/ urine



- Begin Yr 1 for 10% of participants
- Measures cotinine (principal metabolite of nicotine)
- Sensitive to lower cotinine levels when urine is used
- Smoke exposure in past several days
- Positive screen for 'tobacco user': $> 100 \text{ ng/mL}$ cotinine



Introducing salivary hormones in ABCD

Krista Lisdahl
Week 6






Biospecimen Samples.

Sample Type	Purpose	Baseline 9–10 yrs #/participant	1 Year Follow-Up 10–11 yrs #/participant
Screening for Alcohol & Drugs			
Saliva (onsite Dräger)*	Recent Substance Use	1	1
Breath (onsite Breathalyzer)*	Recent Alcohol Use	1	1
Hair (Psychemedics ^a)**	Substance Use	1	1
Urine (NicAlert) ^{**}	Recent Tobacco Use	0	1
Pubertal Hormones			
Saliva (Salimetrics ^b)	Pubertal Hormones	1	1
Genomics/Epigenetics			
Saliva (RUCDR ^c)	Genetics	1	0
Blood (RUCDR ^c) (saliva if refuse blood)	Genetics	0***	0
Timeline of Exposures			
Baby teeth (Dr. Arora – Mt. Sinai ^d)	Environmental Exposures	1	1



Introducing salivary hormones in ABCD: Rationale



Barendse et al., 2020
Frontiers for Young Minds

Morrison et al., 2006
J. Neuroscience

Introducing salivary hormones in ABCD: Rationale



- Onset of puberty
- Duration of pubertal maturation
- Levels of hormones
- Patterns of hormones
- Sensitivity to hormones

- pubertal maturation
 - body
 - brain
- mental health problems
- substance use problems
- behavioral problems

Uban et al., 2018 *DCN*

Herting & Uban et al., 2021 *Frontiers in Endocrinology*

Rationale & methods: Saliva for pubertal hormones



- All participants, 1x/yr, every yr, for 10 consecutive yrs.
- Passive drool
- Measures hormones (testosterone, DHEA, & estradiol in females at birth only).




Step #3 - Allow Saliva to Gently Flow Through the SCA and Into the Cryovial

Tip:
Let saliva pool in your mouth before drooling



© Salimetrics





<https://flipper.diff.org/app/pathways/info/2056>

Uban et al., 2018 *DCN*

Herting & Uban et al., 2021 *Frontiers in Endocrinology*


Rationale & methods: hormones phase 1



Rationale & methods: hormones phase 2



Pubertal Hormone Levels Quality Checking Decision Tree at Baseline



Rationale & methods: hormones phase 2



- Confounding variables

Hormone Levels	Males			Females		
	N	Mean ± SD	IQR	N	Mean ± SD	IQR
DHEA (pg/ml)	2,676	57.78 ± 43.78	50.04	2,430	76.87 ± 56.28	63.15
Testosterone (pg/ml)	2,622	32.80 ± 17.70	21.41	2,358	37.07 ± 18.37	22.94
Estradiol (pg/ml)	-	-	-	2,168	1.17 ± 0.52	0.69
Covariates	N	Mean ± SD	IQR	N	Mean ± SD	IQR
Caffeine in past 12 hours (N)	2,376	Yes = 161/No = 2,210	-	1,707	Yes = 95/No = 1,612	-
Physical activity in past 12 hours (N)	2,366	Yes = 318/No = 2,048	-	1,703	Yes = 216/No = 1,487	-
Time Since Midnight (minutes)	2,381	777.58 ± 181.73	313	1,712	776.53 ± 177.18	311
Collection Duration (minutes)	2,318	6.81 ± 5.44	6	1,676	7.49 ± 5.89	5
Time to Freeze (minutes)	2,335	2.69 ± 12.31	1	1,686	3.05 ± 14.38	1


- oral environment
- flow rate

Herting & Uban et al., 2021 *Frontiers in Endocrinology*

Rationale & methods: hormones phase 2



- Findings: females @ baseline



Rationale & methods: hormones phase 3



- How to use this data?



Hormone Saliva Salimetric Scores (hsss01)		
Salimetrics hormone test mean (pg/mL)	hormone_scr_dhea_mean, hormone_scr_hse_mean, hormone_scr_ert_mean	
Salimetrics hormone test, repetitions 1 and 2 (pg/mL)**	hormone_scr_dhea_rep1, hormone_scr_hse_rep1, hormone_scr_ert_rep1	
Salimetrics hormone test below lower limit of sensitivity, replications 1 and 2**** (yes/no)	hormone_scr_dhea_rep1_II, hormone_scr_hse_rep1_II, hormone_scr_ert_rep1_II	dhea: all, hse (E2), female; ert (T): All
Salimetrics hormone quantity not sufficient, repetitions 1 and 2**** (yes/no)	hormone_scr_dhea_rep1_qns, hormone_scr_hse_rep1_qns, hormone_scr_ert_rep1_qns	
Salimetrics hormone test none detected, repetitions 1 and 2**** (yes/no)	hormone_scr_dhea_rep1_nd, hormone_scr_hse_rep1_nd, hormone_scr_ert_rep1_nd	

A researcher's guide to the measurement and modeling of puberty in the ABCD Study ® at baseline

Theresa W. Cheng^{1*}, Lucia Magis Weinberg², Victoria G. Williamson¹, Cecile D. Ladouceur³, Sarah L. Whittle⁴, Megan Herting⁵, Kristina A. Uban⁶, Michelle L. Byrne⁷, Marjolein E. Barendse¹, Elizabeth A. Shirtcliff⁸, Jennifer H. Pfeifer¹


¹University of Oregon, United States, ²University of California, Berkeley, United States, ³University of Pittsburgh, United States, ⁴The University of Melbourne, Australia, ⁵Keck School of Medicine, University of Southern California, United States, ⁶University of California, Irvine, United States, ⁷Monash University, Australia, ⁸Iowa State University, United States

Submitted to Journal:
Frontiers in Endocrinology

Specialty Section:
Pediatric Endocrinology



- Some saliva @ baseline
- Blood @ Yr 2 for 100% of participants
- Smokescreen genotyping array, epigenetics coming
- Details in 3.0 release notes & accompanying README files



Methodology article | [Open Access](#) | Published: 27 February 2016

Smokescreen: a targeted genotyping array for addiction research

[James W. Baurley](#)✉, [Christopher K. Edlund](#), [Carissa I. Pardamean](#), [David V. Conti](#) & [Andrew W. Bergen](#)

[BMC Genomics](#) **17**, Article number: 145 (2016) | [Cite this article](#)

2993 Accesses | **16** Citations | **2** Altmetric | [Metrics](#)

> [Hypertension](#). 2020 Jan;75(1):59–70. doi: 10.1161/HYPERTENSIONAHA.118.12292.
Epub 2019 Dec 2.

Influence of Dietary Approaches to Stop Hypertension-Type Diet, Known Genetic Variants and Their Interplay on Blood Pressure in Early Childhood: ABCD Study

Mohammad Hadi Zafarmand ¹ ², Marit Spanjer ¹, Mary Nicolaou ¹, Hanneke A H Wijnhoven ³, Barbera D C van Schaik ⁴, Andre G Uitterlinden ⁵ ⁶, Harold Snieder ⁷, Tanja G M Vrijkotte ¹

Affiliations + expand

PMID: 31786974 DOI: 10.1161/HYPERTENSIONAHA.118.12292

Rationale & methods: Exposures w/ baby teeth



- On-going collection from all participants Uban et al., 2018 *DCN*
- Sub-study (n=500) sent to Manish Arora's lab NIH grant – Elizabeth Sowell
- 2nd trimester *in utero* through time of shed tooth
- Weekly averages of Pb and Mn



Tooykrub/shutterstock, Ocskay Bence/shutterstock



On-going sub-studies that collect new specimens or analyze biobanked specimens

Blood Sample Collection

939 Shared Subjects

DESCRIPTION

N/A

SHORT NAME

bsc01


DATA TYPE

Clinical Assessments

CATEGORY

Summary

DISTRIBUTION FOR BSC01 / ACTH




[Add Data Structure](#)

[Create Element Filter](#)

Other ‘biomarkers’ in ABCD



- Biological specimens
- Physiological measures



Some general Do's and Don'ts



- Do . . .
 - Plot out all individual data for biomarkers and collection variables to identify physiologically or improbable values
 - Publish decision trees and scripts
 - Read all previously published articles with biospecimen
 - Work with expert on biospecimen data
 - Consider sociodemographic factors, sample bias, and methods
 - Report effect sizes
- Don't . . . Be scared! You can do it – create your dream team!

Acknowledgements



Elizabeth Sowell, CHLA, USC

Doug Granger, UCI, IISBR, Salimetrics

Eric Kan, CHLA

Megan Herting, USC

Stefanie Bodison, USC

Marybel Gonzalez, UCSD

ABCD ReproNim team:

Angie Laird

David Kennedy

Satra Ghosh

JB Poline

UCI Developing Brain Laboratory members:

Vida Rebello

Nneoma Uba

Hawa Mariko

Salma Nazarazi

Minhaz Mohsin

Jamie Atienza


Babette Steigelmann

Savannah Tan

Leila Nazarazi

Hania Alim

Christian Black



Claudia Chavez

IISBR at UCI colleagues

Hillary Piccerillo

Elizabeth Thomas

Jenna Riis

Michael Hoyt

Kate Kuhlman

Alyson Zalta

Ilona Yim

